• Je něco špatně v tomto záznamu ?

Comparative analysis of loss of heterozygosity and expression profile in normal tissue, DCIS and invasive breast cancer

M. Zikan, J. Bohm, D. Pavlista, D. Cibula

. 2011 ; 13 (9) : 652-655.

Jazyk angličtina Země Itálie

Typ dokumentu srovnávací studie, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc12022188

Grantová podpora
NS10566 MZ0 CEP - Centrální evidence projektů

INTRODUCTION: Ductal carcinoma in situ (DCIS) is considered to be related to the development of invasive breast cancer. The aim of molecular biological research of preinvasive breast lesion characteristics and comparison with normal tissues and tissue of invasive tumours is to identify patients at high risk of developing invasive tumour on the basis of already established preinvasive lesions, and thus influence clinical decision-making. The aim of our study was to analyse several key molecules involved in different cellular pathways important for cancer development and progression in different types of breast tissue and to describe similarities and differences between premalignant and malignant lesions. MATERIAL AND METHODS: Genetic material isolated from both the tumour and healthy tissue was examined by loss of heterozygosity (LOH) analysis and real-time PCR using collagen 2A as a house-keeping gene. RESULTS: We analysed 65 samples of healthy mammary gland, 25 DCIS and 42 invasive ductal breast cancer samples. We analysed the LOH in three genes: BRCA1, BRCA2 and p53; and the gene expression of the VEGF gene and Bcl-2 gene. LOH in the BRCA1 gene was present in 44.74% of invasive samples and in 8.69% of DCIS (p=0.026); LOH in the BRCA2 gene in 45.0% of invasive samples and in 9.52% of DCIS (p=0.036); LOH in the p53 gene in 32.5% of invasive samples and in 31.82% of DCIS (p=0.97). No LOH was observed in normal tissue samples. VEGF was overexpressed in 14.3% of invasive cancers and in 12.0% of DCIS. Overexpression of Bcl-2 was observed in 11.9% of invasive cancers and in 8.0% of DCIS. CONCLUSION: We have confirmed that some of the molecular characteristics of DCIS are identical to those of invasive carcinoma. This approach could lead to the identification of molecular markers as indicators for the potential development of DCIS into invasive carcinoma or identification of DCIS subgroups with latent invasion.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12022188
003      
CZ-PrNML
005      
20190430165700.0
007      
ta
008      
120806s2011 it f 000 0#eng||
009      
AR
024    7_
$a 10.1007/s12094-011-0710-1 $2 doi
035    __
$a (PubMed)21865136
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a it
100    1_
$a Zikán, Michal, $d 1976- $7 xx0096708 $u Oncogynecologic Center, Department of Obstetrics and Gynecology, Charles University in Prague, First Faculty of Medicine and General University Hospital, Apolinarska 18, Prague 2, Czech Republic
245    10
$a Comparative analysis of loss of heterozygosity and expression profile in normal tissue, DCIS and invasive breast cancer / $c M. Zikan, J. Bohm, D. Pavlista, D. Cibula
520    9_
$a INTRODUCTION: Ductal carcinoma in situ (DCIS) is considered to be related to the development of invasive breast cancer. The aim of molecular biological research of preinvasive breast lesion characteristics and comparison with normal tissues and tissue of invasive tumours is to identify patients at high risk of developing invasive tumour on the basis of already established preinvasive lesions, and thus influence clinical decision-making. The aim of our study was to analyse several key molecules involved in different cellular pathways important for cancer development and progression in different types of breast tissue and to describe similarities and differences between premalignant and malignant lesions. MATERIAL AND METHODS: Genetic material isolated from both the tumour and healthy tissue was examined by loss of heterozygosity (LOH) analysis and real-time PCR using collagen 2A as a house-keeping gene. RESULTS: We analysed 65 samples of healthy mammary gland, 25 DCIS and 42 invasive ductal breast cancer samples. We analysed the LOH in three genes: BRCA1, BRCA2 and p53; and the gene expression of the VEGF gene and Bcl-2 gene. LOH in the BRCA1 gene was present in 44.74% of invasive samples and in 8.69% of DCIS (p=0.026); LOH in the BRCA2 gene in 45.0% of invasive samples and in 9.52% of DCIS (p=0.036); LOH in the p53 gene in 32.5% of invasive samples and in 31.82% of DCIS (p=0.97). No LOH was observed in normal tissue samples. VEGF was overexpressed in 14.3% of invasive cancers and in 12.0% of DCIS. Overexpression of Bcl-2 was observed in 11.9% of invasive cancers and in 8.0% of DCIS. CONCLUSION: We have confirmed that some of the molecular characteristics of DCIS are identical to those of invasive carcinoma. This approach could lead to the identification of molecular markers as indicators for the potential development of DCIS into invasive carcinoma or identification of DCIS subgroups with latent invasion.
650    _2
$a nádory prsu $x genetika $x patologie $7 D001943
650    _2
$a duktální karcinom prsu $x genetika $x patologie $7 D018270
650    _2
$a intraduktální neinfiltrující karcinom $x genetika $x patologie $7 D002285
650    _2
$a mutační analýza DNA $7 D004252
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a stanovení celkové genové exprese $7 D020869
650    _2
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a geny BRCA1 $7 D019398
650    _2
$a geny BRCA2 $7 D024522
650    _2
$a geny bcl-2 $7 D019254
650    _2
$a geny p53 $7 D016158
650    _2
$a lidé $7 D006801
650    _2
$a ztráta heterozygozity $x genetika $7 D019656
650    _2
$a invazivní růst nádoru $7 D009361
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Böhm, Jan $7 _AN042460
700    1_
$a Pavlišta, David $7 xx0057882
700    1_
$a Cibula, David, $d 1968- $7 jo20000074072
773    0_
$w MED00180195 $t Clinical & translational oncology official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico $x 1699-3055 $g Roč. 13, č. 9 (2011), s. 652-655
856    41
$u https://pubmed.ncbi.nlm.nih.gov/21865136 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m $z 0
990    __
$a 20120806 $b ABA008
991    __
$a 20190430165745 $b ABA008
999    __
$a ok $b bmc $g 944101 $s 779485
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2011 $b 13 $c 9 $d 652-655 $i 1699-3055 $m Clinical & translational oncology. $n Clin Transl Oncol $x MED00180195
GRA    __
$a NS10566 $p MZ0
LZP    __
$b NLK111 $a Pubmed-20120806/12/01

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...